Absence of PNH-clones in DDX41mutant-GPS aids in their distinction from acquired BM failure syndromes
Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), James M. Foran(Memorial Sloan Kettering Cancer Center), Timothy M. Chlon(Cincinnati Children's Hospital Medical Center), Hassan B. Alkhateeb(Mayo Clinic), Alejandro Ferrer(Mayo Clinic), Christy M. Finke(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Aref Al‐Kali(Mayo Clinic), Terra Lasho(Toyota Motor Corporation (Switzerland)), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 1
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Inherited antithrombin deficiency: a review
|Haemophilia|2008|396
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297